India Drafts Guidelines To Require CRO Registration Of Trials
This article was originally published in PharmAsia News
India is considering a requirement that clinical research companies in the country register both themselves and the trials they run. The nation's health ministry has drafted guidelines for registration, intended in part to prevent unethical experiments on humans. Drug Controller General of India Surinder Singh said the draft, being reviewed by an internal committee, was drawn up in part with the World Health Organization and volunteering companies. The next step is for the guidelines to be presented to the Drugs Technical Advisory Board for approval, with the new rules expected to be in place before the new year. (Click here for more
You may also be interested in...
A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.